Publisher
Springer International Publishing
Reference42 articles.
1. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanism across eight psychiatric disorders. Cell. 2019;179:1466–82.
2. Krogmann A, Peters L, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.
3. Meltzer HY, Rajagopal L, Matrisciano F, Hao J, Svensson KA, Huang M. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav Brain Res. 2019;361:139–15.
4. Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest. 2013;123(12):4986–91.
5. Meltzer HY. Pharmacotherapy of cognition in schizophrenia. Curr Opin Behav Sci. 2015;4:115–21.